Published in Prostate on August 01, 2001
Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates. J Urol (2010) 1.66
Pre-treatment risk stratification of prostate cancer patients: A critical review. Can Urol Assoc J (2012) 0.99
Predictive Factors for Prostate Cancer in Biopsy of Patients with Prostate-Specific Antigen Levels Equal to or Less Than 4 ng/ml. Korean J Urol (2011) 0.95
The CR-CO discrepancy and its effect on cephalometric measurements. Angle Orthod (1994) 3.30
High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo (1995) 3.25
The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol (1993) 2.95
Extraskeletal osteosarcoma. A clinicopathologic review of 26 cases. Cancer (1990) 2.56
Mixed epithelial and stromal tumor of the kidney. Am J Surg Pathol (2000) 2.24
Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ (1994) 2.13
Recording condylar movement with two facebow systems. Angle Orthod (1996) 2.13
What young men know about testicular cancer. Prev Med (1983) 2.08
Prognostic implications of a positive apical margin in radical prostatectomy specimens. J Urol (1997) 1.83
Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 1.67
Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol Cell Biol (1997) 1.59
Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res (1995) 1.58
Chromosomal analysis of renal angiomyolipoma by comparative genomic hybridization: evidence for clonal origin. Hum Pathol (1999) 1.57
De novo muscle invasive bladder cancer: is there a change in trend? J Urol (2001) 1.54
Recursive partitioning for prognostic grouping of patients with clinically localized prostate carcinoma. Cancer (2000) 1.50
Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res (1999) 1.48
Secondary tumors of the prostate. J Urol (1985) 1.48
Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol (1996) 1.46
Intralesional treatment of established murine primary renal tumor with interleukin-4: localized effect on primary tumor with no impact on metastases. J Urol (1995) 1.44
Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev (2001) 1.43
Current status of tissue markers as prognostic factors in prostatic adenocarcinoma. Int J Radiat Oncol Biol Phys (1995) 1.41
A comparison of the W-stapled ileal reservoir with hand-sewn reservoirs for orthotopic bladder replacement. Urology (1996) 1.40
Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res (1995) 1.38
P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol (2002) 1.33
Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res (1998) 1.33
High flow malignant priapism with isolated metastasis to the corpora cavernosa. Urology (1998) 1.31
Concurrent angiomyolipoma and renal cell neoplasia: a study of 36 cases. Mod Pathol (2001) 1.31
Conservative surgery for renal cell carcinoma: a single-center experience with 100 patients. J Urol (1989) 1.26
Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res (1994) 1.24
Surgical complications of bladder augmentation: comparison between various enterocystoplasties in 133 patients. Urology (2000) 1.23
Renal cell carcinoma with inferior vena cava tumor thrombi. Surg Gynecol Obstet (1991) 1.22
Cytogenetic studies of tumor tissue from patients with nonfamilial renal cell carcinoma. Cancer Res (1986) 1.22
Diet in the epidemiology of carcinoma of the prostate gland. J Natl Cancer Inst (1983) 1.22
Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer (1989) 1.21
College of American Pathologists Conference XXXV: solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants. Arch Pathol Lab Med (2000) 1.17
Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res (2001) 1.17
Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol (1998) 1.16
Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology (1995) 1.14
Experience with cardiopulmonary bypass and deep hypothermic circulatory arrest in the management of retroperitoneal tumors with large vena caval thrombi. Ann Surg (1990) 1.13
Management of primary urethral cancer. Urology (1998) 1.13
Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology (2000) 1.11
The prostatic capsule: does it exist? Its importance in the staging and treatment of prostatic carcinoma. Am J Surg Pathol (1989) 1.10
Focal xanthogranulomatous pyelonephritis presenting as a renal tumor with vena caval thrombus. J Urol (1998) 1.10
College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee. Arch Pathol Lab Med (1995) 1.10
Local anesthesia for ultrasound guided prostate biopsy: a prospective randomized trial comparing 2 methods. J Urol (2001) 1.09
Outcome of palliative urinary diversion in the treatment of advanced malignancies. Cancer (1999) 1.07
Epidemiology of high grade prostatic intraepithelial neoplasia. Pathol Res Pract (1995) 1.07
Sarcomatoid renal cell carcinoma. An immunohistochemical study of 18 cases. Arch Pathol Lab Med (1993) 1.06
Sexual function after radical prostatectomy. Prostate (1986) 1.06
Topical instillation of doxorubicin hydrochloride in the treatment of recurring superficial transitional cell carcinoma of the bladder. J Urol (1977) 1.05
High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res (1996) 1.05
Mixed epithelial and stromal tumor of the kidney lacks the genetic alterations of cellular congenital mesoblastic nephroma. Hum Pathol (2001) 1.05
Blue nevus and melanosis of the prostate. Electron-microscopic and immunohistochemical studies. Am J Clin Pathol (1988) 1.05
Translocation (X;1) in papillary renal cell carcinoma. A new cytogenetic subtype. Cancer Genet Cytogenet (1993) 1.05
The use of tolterodine in children after oxybutynin failure. BJU Int (2003) 1.05
Anterior urethral injuries: four years of experience at the Detroit General Hospital. J Urol (1978) 1.04
Screening for prostate cancer. The challenge of promoting informed decision making in the absence of definitive evidence of effectiveness. Med Clin North Am (1999) 1.04
Metastatic breast carcinoma to the bladder. J Urol (1970) 1.04
The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol (1982) 1.04
Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer (1983) 1.04
Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am J Surg Pathol (2000) 1.04
Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer (1980) 1.03
Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Prostate (1989) 1.03
Urological injuries associated with pelvic trauma. J Urol (1979) 1.03
Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610. J Clin Oncol (2003) 1.02
Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland: a basis for checklists. Cancer Committee. Arch Pathol Lab Med (2000) 1.01
Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res (2000) 1.01
Lymph node size does not correlate with the presence of prostate cancer metastasis. Urology (1999) 1.01
Should the age specific prostate specific antigen cutoff for prostate biopsy be higher for black than for white men older than 50 years? J Urol (2000) 1.01